Proceedings of ICBioMed 2025 Symposium: Computational Modelling and Simulation for Biology and Medicine
DOI: 10.54254/2753-8818/2025.LD26074

Gut Microbiota Dysbiosis and Depression: Pathological Mechanisms and the Therapeutic Potential of Probiotic Interventions

Yifan Wang

Beijing University Of Technology, Beijing, China
wangyf2004@126.com

Abstract. Major depressive disorder (MDD) causes a substantial global health burden, yet current pharmacological and psychotherapeutic treatments often yield delayed or incomplete relief and carry undesirable side effects. Research on the gut brain axis describes a bidirectional network in which microbial metabolites modulate limbic regions via vagal pathways, intestinal barrier disruption and endotoxin induced inflammation activate systemic and central immune responses, and shifts in tryptophan metabolism reduce serotonin precursor availability while generating neurotoxic compounds. Clinical and preclinical studies suggest that probiotic supplementation can alleviate depressive symptoms and restore key biomarkers of neuroplasticity and inflammation, sometimes in combination with standard antidepressant regimens. However, variability in strain efficacy and host responses poses challenges for clinical translation. Future investigations leveraging large scale multiomics profiling, real time microbiome monitoring and artificial intelligence driven patient stratification will be essential to develop precision microbial interventions and integrate them into comprehensive depression treatment strategies. This review evaluates the mechanistic links between gut microbiota dysbiosis and depression and synthesizes current evidence for probiotics as adjunctive therapy.

Keywords: major depressive disorder, MDD, probiotics, gut microbiota dysbiosis

1. Introduction

Major depressive disorder is a complex psychiatric illness characterized by persistent low mood, loss of interest and cognitive impairment. As a leading cause of years lived with disability, depression has become the second largest contributor to global disease burden after cardiovascular disease. Chronic relapse and lifelong risk render MDD a primary driver of disability adjusted life years (DALYs). Current treatment relies predominantly on pharmacotherapy, mainly antidepressants that target neurotransmitter systems, and psychotherapy. Both approaches are limited by delayed onset of efficacy, incomplete remission, treatment resistance, medication side effects and the need for prolonged patient engagement. Moreover, the multifactorial and poorly understood etiology of depression, compounded by social and environmental influences, further complicates therapeutic success and contributes to high prevalence and enduring morbidity.

© 2025 The Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

DOI: 10.54254/2753-8818/2025.LD26074

Emerging evidence from clinical and animal studies implicates gut microbiota dysbiosis as a contributing factor in depression through several intersecting mechanisms. Disrupted microbial communities compromise the intestinal mucosal barrier, permitting translocation of bacterial endotoxins such as lipopolysaccharide (LPS) into the circulation, which activates systemic and neuro inflammatory pathways. Concurrently, dysbiosis alters the biosynthesis of key neurotransmitters such as serotonin, gamma aminobutyric acid (GABA) and norepinephrine and perturbs hypothalamic pituitary adrenal (HPA) axis function, heightening stress sensitivity. These intertwined pathological processes not only increase susceptibility to MDD but also exacerbate its clinical manifestations.

Probiotic intervention, as an emerging strategy to restore microbial balance, shows promise in adjunctive depression therapy. By competitively colonizing intestinal niches and consuming nutrients, probiotic strains inhibit pathogen overgrowth and secrete antimicrobial peptides. They also reinforce mucosal barrier integrity by upregulating tight junction proteins, reducing endotoxin translocation. Certain strains directly synthesize neuroactive compounds, increasing prefrontal dopamine or serotonin precursor supply to modulate brain function. Randomized controlled trials have demonstrated that specific probiotics can significantly ameliorate mild depressive symptoms. This review examines the mechanisms by which gut microbiota dysbiosis contributes to depression and evaluates the therapeutic potential of probiotic and related microbial interventions, offering new insights for early diagnosis and personalized treatment strategies in MDD.

2. Gut-brain axis and its association with depression

2.1. Neural pathways

The gut and brain are connected through multiple pathways that form an integrated network. The first is the neural pathway, in which the vagus nerve is critical for signal transmission between the gut and the brain. Neural communication is bidirectional. Afferent signaling carries information from the gut to the brain: vagal nerve endings in the intestinal mucosa detect chemical signals released by enterochromaffin cells, such as serotonin precursors released in response to microbial short-chain fatty acids, or mechanical stimuli. These signals travel along vagal afferent fibers to the brainstem and are then relayed to higher emotional centers such as the amygdala and hippocampus. A separate afferent route, the spinal-thalamic pathway, conveys nociceptive signals from gut injury or inflammation to the thalamus. Efferent signaling carries commands from the brain to the gut: it originates in the brainstem vagal nuclei and reaches intestinal smooth muscle and glands to regulate motility and secretion. Under stress, this pathway may inhibit gut function and worsen gastrointestinal symptoms.

2.2. Immune pathways

The second major route is the immune pathway, which describes how gut mucosal immunity influences systemic and central inflammation. When dysbiosis occurs, beneficial bacteria decrease and pathogens proliferate, damaging the mucosal barrier and reducing expression of tight junction proteins such as occludin and ZO-1. This allows bacterial endotoxins, primarily lipopolysaccharide (LPS), to enter the circulation. LPS activates the immune system and raises proinflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α) and interleukin-1β (IL-1β). For example, depressed patients exhibit serum LPS levels two to three times higher than healthy controls [1], and IL-6 levels are elevated by about 40% [2]. These cytokines can reach the brain via

DOI: 10.54254/2753-8818/2025.LD26074

weakened regions of the blood–brain barrier or active transport, or they can activate vagal afferents, ultimately triggering microglial activation and neuroinflammation. Sustained low-grade neuroinflammation is closely linked to the pathogenesis of depression.

2.3. Metabolic pathways

The metabolic pathway centers on microbial regulation of key nutrients, especially tryptophan. Gut microbes determine the fate of dietary tryptophan: roughly 60% is shunted into the kynurenine pathway, while only about 1% is used for serotonin synthesis [3]. This balance is crucial for mood because kynurenine crosses into the brain and is converted into neurotoxic quinolinic acid, which damages neurons in regions such as the hippocampus that are vital for emotion and memory. Dysbiosis leading to increased kynurenine production both reduces serotonin precursor availability and raises neurotoxin levels, thereby increasing depression risk. Additionally, certain Lactobacillus and Bifidobacterium species produce γ-aminobutyric acid (GABA), and some Escherichia and yeast strains generate norepinephrine precursors. These microbially derived neuroactive compounds provide an endogenous source of signaling molecules.

2.4. Key pathological processes

Persistent dysbiosis triggers a cascade of pathological processes that can lead to depression. Barrier dysfunction permits LPS translocation, provoking systemic and neuroinflammation; in depressed patients and models, TNF-α and IL-1β levels rise three- to fivefold [4]. Neurotransmitter synthesis is also altered: the gut normally synthesizes 90% of the body's serotonin, yet depressed individuals show up to a 50% decline in serotonin-producing bacteria [5]. GABA-producing species likewise decrease, potentially lowering central GABA and contributing to anxiety. Bacterial groups involved in norepinephrine precursor production may also be reduced. Finally, healthy microbiota help maintain HPA axis feedback sensitivity to cortisol. Dysbiosis blunts this regulation, leading to chronic cortisol elevation, up to 200% in animal models, with neurotoxic effects that worsen mood disturbances [6].

3. Clinical and experimental evidence

3.1. Metagenomic analyses of gut microbiota in depressed patients

Clinical studies have demonstrated a strong association between gut microbiota composition and depression. Large-scale metagenomic analyses comparing depressed patients to healthy controls reveal significant differences in both microbial community structure and function. For example, in a cohort of 1 054 participants (including depressed patients and healthy individuals), the abundance of key beneficial taxa was markedly reduced in depressed subjects: Bacteroidetes decreased by approximately 30 percent and Bifidobacterium by about 40 percent [7]. In contrast, putative pathogens such as members of Enterobacteriaceae increased by roughly 50 percent and certain Clostridium species by about 25 percent. Metabolic profiling further showed a significant decline in anti-inflammatory short-chain fatty acids, especially butyrate and propionate, with average reductions of up to 60 percent. Concurrently, the plasma ratio of kynurenine to tryptophan (Kyn/Trp), reflecting enhanced diversion of tryptophan toward the neurotoxic kynurenine pathway, rose by approximately 35 percent, indicating upregulation of this depressive-associated metabolic route [8].

DOI: 10.54254/2753-8818/2025.LD26074

3.2. Functional validation in animal models

Animal experiments have provided causal evidence linking microbiota alterations to depressive-like behaviors. Germ-free mice receiving fecal transplants from depressed patients exhibit pronounced depressive phenotypes: in the forced swim test, immobility time increases by about 50 percent, and hippocampal expression of brain-derived neurotrophic factor (BDNF) declines by roughly 30 percent, indicating impaired neuroplasticity [4]. In stress-induced models, such as chronic restraint stress or social defeat, animals develop anhedonia, social withdrawal and behavioral despair alongside marked dysbiosis. Chronic restraint stress, for example, leads to a 90 percent loss of Lactobacillus in the mouse gut, elevated interleukin-6 levels and cognitive deficits [9]. Manipulating the microbiota with antibiotics exacerbates these depressive behaviors, while supplementation with specific probiotic strains can attenuate them, further demonstrating that gut microbial composition directly mediates stress-induced changes in mood and brain function.

4. Probiotic interventions

4.1. Mechanisms of probiotic action

Probiotics can modulate the gut–brain axis and improve depressive symptoms through multiple pathways. First, competitive colonization and antimicrobial peptide secretion. Strains such as Lactobacillus and Bifidobacterium compete for intestinal adhesion sites and nutrients, inhibiting pathogen overgrowth. They also secrete bacteriocins and other antimicrobial peptides that directly kill or suppress harmful microbes, helping to restore a healthy microbial balance. Second, restoration of mucosal barrier integrity and tight junction regulation. Probiotics stimulate mucus secretion by intestinal epithelial cells and upregulate tight junction proteins such as ZO-1 and occludin. Third, synthesis of neuroactive compounds and precursor supply. Certain Lactobacillus and Bifidobacterium species produce γ-aminobutyric acid, while Escherichia and some yeast strains generate norepinephrine precursors. Probiotics also influence host metabolic pathways, increasing availability of serotonin precursors. In animal studies, supplementation with Lactobacillus plantarum PS128 raised prefrontal dopamine by about 40 percent and serotonin by about 25 percent [5]. Fourth, immune modulation and downregulation of inflammatory mediators. Probiotics enhance production of anti-inflammatory cytokines such as interleukin-10 and suppress overexpression of proinflammatory cytokines including TNF-α, IL-6 and IL-1β. Both clinical and animal studies have shown that Bifidobacterium strains can reduce these cytokines by more than 50 percent, thereby alleviating systemic and neuroinflammation [10].

4.2. Clinical trials and future prospects

Clinical trials support the antidepressant potential of probiotic supplementation. In a randomized controlled trial of 40 patients with severe MDD, an eight-week regimen of a multi-strain probiotic containing various Lactobacillus and Bifidobacterium strains led to a significant reduction in HAM-D scores by an average of 36 percent ($p < 0.01$) and an 18 percent increase in serum BDNF levels, indicating enhanced neuroplasticity [11]. Another study in healthy volunteers found that Bifidobacterium longum 1714 reduced perceived stress scores by 20 percent ($p = 0.01$), suggesting strain-specific effects on stress-related mood [12]. Despite these promising results, probiotic efficacy varies significantly by strain and by individual. Host microbiome composition, genetics and lifestyle factors influence probiotic colonization and therapeutic outcome. A standardized “strain-phenotype”

DOI: 10.54254/2753-8818/2025.LD26074

matching framework is not yet established, making it difficult to tailor probiotic therapy to specific depressive subtypes such as anxiety-predominant or anhedonic presentations. Future research must address these challenges by elucidating strain-specific mechanisms, conducting large-scale, rigorously controlled clinical trials with long-term follow-up and developing precision intervention strategies to integrate microbial therapy into psychiatric practice.

5. Conclusion

The gut microbiota establishes a complex communication network with the brain via vagal sensory and motor pathways, immune modulation of the mucosal barrier, and neurochemical effects of tryptophan metabolism. Vagal afferents detect short-chain fatty acids and neurotransmitter precursors in the intestine and relay these signals to the brainstem, amygdala, and hippocampus. Dysbiosis compromises tight junctions, allowing lipopolysaccharide and other endotoxins to enter the circulation and trigger systemic and central inflammation. Concurrently, microbial shifts divert tryptophan toward the neurotoxic kynurenine pathway, reducing serotonin precursor availability. Together, these mechanisms converge to increase susceptibility to depression and exacerbate its progression. Multiple randomized controlled trials and animal studies have confirmed that specific probiotic strains can effectively modulate the gut–brain axis. Probiotics compete for adhesion sites and secrete antimicrobial peptides to inhibit pathogens, reinforce the mucosal barrier to reduce endotoxin translocation, synthesize γ-aminobutyric acid and enhance serum 5-hydroxytryptamine precursor supply, and upregulate brain-derived neurotrophic factor while suppressing proinflammatory cytokines such as TNF-α, IL-6 and IL-1β by up to 50 percent. These combined actions translate into measurable improvements in depressive and anxiety symptoms and a strong safety and tolerability profile for probiotic interventions.

Future research must address both standardization and personalization of probiotic therapy. Large-scale, multicenter clinical trials are needed to define optimal strains, dosing regimens and treatment duration. At the same time, integration of metagenomic, metabolomic and immunologic data with machine learning will enable development of “microbiome-depression phenotype” matching tools. Such precision approaches can tailor probiotic combinations to anxiety-predominant, anhedonic or cognitive-impairment subtypes and leverage advanced delivery systems, including microencapsulation and nanocarriers, to enhance colonization and efficacy. In clinical practice, microbial interventions, including probiotics, prebiotics and fecal microbiota transplantation, should be combined with antidepressant medications and psychotherapy to create a coordinated “microbe–drug-mind” treatment paradigm. Evidence already supports synergistic benefits of probiotic plus SSRI co-administration in improving response rates and reducing gastrointestinal side effects, prebiotic-probiotic combinations in further lowering depressive scores, and fecal transplants in treatment-resistant cases. By integrating these multimodal strategies, it may be possible to overcome current therapeutic limitations and substantially improve long-term outcomes and quality of life for individuals with depression.

References

[1] Maes, M., Kubera, M., & Leunis, J. C. (2008). The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro endocrinology letters, 29(1), 117–124.

[2] Dowlati, Y., Herrmann, N., Swardfager, W., Liu, H., Sham, L., Reim, E. K., & Lanctôt, K. L. (2010). A meta-analysis of cytokines in major depression. Biological psychiatry, 67(5), 446–457.

DOI: 10.54254/2753-8818/2025.LD26074

[3] O'Mahony, S. M., Clarke, G., Borre, Y. E., Dinan, T. G., & Cryan, J. F. (2015). Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behavioural brain research, 277, 32–48.
[4] Kelly, J. R., Borre, Y., O' Brien, C., Patterson, E., El Aidy, S., Deane, J., Kennedy, P. J. (2016). Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat. Journal of psychiatric research, 82, 109–118.
[5] Prehn-Kristensen, A., Zimmermann, A., Tittmann, L., Lieb, W., Schreiber, S., Baving, L., & Fischer, A. (2018). Reduced microbiome alpha diversity in young patients with ADHD. PloS one, 13(7), e0200728.
[6] Sudo, N., Chida, Y., Aiba, Y., Sonoda, J., Oyama, N., Yu, X. N., Kubo, C., & Koga, Y. (2004). Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. The Journal of physiology, 558(Pt 1), 263–275.
[7] Zheng, P., Zeng, B., Zhou, C., Liu, M., Fang, Z., Xu, X., Zeng, L., Chen, J. (2016). Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Molecular psychiatry, 21(6), 786–796.
[8] Valles-Colomer, M., Falony, G., Darzi, Y., Tigchelaar, E. F., Wang, J., Tito, R. Y. (2019). The neuroactive potential of the human gut microbiota in quality of life and depression. Nature microbiology, 4(4), 623–632.
[9] Marin, I. A., Goertz, J. E., Ren, T., Rich, S. S., Onengut-Gumuscu, S., Farber, E., Wu, M. (2017). Microbiota alteration is associated with the development of stress-induced despair behavior. Scientific reports, 7, 43859.
[10] Akbari, E., Asemi, Z., Daneshvar Kakhaki, R., Bahmani, F., Kouchaki, E., Tamtaji, O. R., Hamidi, G. A., & Salami, M. (2016). Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. Frontiers in aging neuroscience, 8, 256.
[11] Schmidt, K., Cowen, P. J., Harmer, C. J., Tzortzis, G., Errington, S., & Burnet, P. W. (2015). Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology, 232(10), 1793–1801.
[12] Allen, A. P., Hutch, W., Borre, Y. E., Kennedy, P. J., Temko, A., Boylan, G., Murphy, E., Cryan, J. F., Dinan, T. G., & Clarke, G. (2016). Bifidobacterium longum 1714 as a translational psychobiotic: modulation of stress, electrophysiology and neurocognition in healthy volunteers. Translational psychiatry, 6(11), e939.